Crossmark

Prospective validation of gas man simulations of sevoflurane in O2/air over a wide fresh gas flow range

Published Online: 2022-03-22

Published Print: 2022-12

Authors

Candries, Esther https://orcid.org/0000-0003-2056-9969
De Wolf, Andre M.

Hendrickx, Jan F. A.
License Information

Text and Data Mining valid from 2022-03-22

Version of Record valid from 2022-03-22
More Information

Article History

Received: 7 January 2022

Accepted: 5 March 2022

First Online: 22 March 2022

Declarations

:

: Jan Hendrickx has received lecture support, travel reimbursements, equipment loans, consulting fees and/or meeting organizational support from a number of companies involved with inhaled agent delivery (alphabetically): AbbVie, Acertys, Air Liquide, Allied Healthcare, Armstrong Medical, Baxter, Dräger, GE, Hospithera, Heinen und Löwenstein, Intersurgical, Maquet, MDMS, MEDEC, Micropore, Molecular, NWS, Philips, Quantum Medical. The other authors declare that they have no conflict of interest.

: This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the Institutional Review Board of the OLV Hospital in Aalst, Belgium (OLV study 2021/075 B1262021000014).

: Informed consent was obtained from all individual participants included in the study.

Document is current